Dihexa

Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide or PNB-0408, is a cognitive classification research peptide that functions as an HGF/c-Met activator. This small peptide compound has been developed to mimic the effects of brain-derived neurotrophic factor (BDNF) in laboratory studies. The mechanism of action involves Dihexa binding to hepatocyte growth factor (HGF) and its receptor c-Met, pathways that research indicates are involved in neural development and synaptic plasticity. In research models, studies suggest that Dihexa promotes neurogenesis and facilitates synapse formation, potentially enhancing cognitive function through the repair and growth of neural connections. Primary research effects observed in laboratory studies include enhanced cognitive function, promotion of neurogenesis, facilitation of synapse formation, improved memory retention, and support for neural repair processes. These effects make Dihexa a compound of interest for researchers investigating cognitive enhancement mechanisms and neural plasticity. However, the evidence grade for Dihexa is classified as D, with significant limitations noted in the research literature. Notably, Fosgonimeton, a clinical derivative of Dihexa, failed its Phase 2 LIFT-AD trial involving 312 patients in September 2024. Additionally, researchers should be aware that the HGF/c-Met pathway has been identified as a pro-cancer pathway in some studies. Currently, there is no validated human experimental parameters procedure established for this compound, reinforcing its designation for laboratory research use only.